FCGR1A and inflammatory bowel disease: Clinically, similar observations have been made in humans, where IBD patients treated concurrently with antidepressants experienced lower relapse rates, reduced steroid usage, fewer endoscopies in the years following study enrolment, and even a selectively protective effect for CD64,65.